Related Experiment Videos
Doripenem
David L Paterson1, Daryl D Depestel
1The University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Australia. david.antibiotics@gmail.com
Abstract:
Carbapenems play a significant role in the current antibiotic armamentarium. Doripenem is the newest carbapenem to be commercially released. Its antimicrobial spectrum more closely resembles those of meropenem and imipenem than that of ertapenem. Thus, it has significant in vitro activity against streptococci, methicillin-susceptible staphylococci, Enterobacteriaceae (including extended-spectrum beta-lactamase-producing strains), Pseudomonas aeruginosa, Acinetobacter species, and Bacteroides fragilis. Doripenem does not have clinically useful activity against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and the majority of gram-negative bacilli that are resistant to meropenem or imipenem. In vitro, resistant P. aeruginosa mutants appear to be harder to select with doripenem than with other carbapenems. Doripenem has been approved for use in treatment of complicated intra-abdominal infection and complicated urinary tract infection. Studies of hospital-acquired pneumonia have also been completed, including one that used a 4-h infusion to enhance the pharmacodynamic profile. In vitro, doripenem lacks the propensity to cause seizures, and a low risk of seizures has been demonstrated in clinical studies. Currently unanswered questions regarding doripenem include the utility and dosing in neonatal, pediatric, and cystic fibrosis populations and specific dosage recommendations for patients receiving hemodialysis, peritoneal dialysis, or continuous renal replacement therapies. The longevity of doripenem will depend on our ability to curtail the spread of carbapenem-resistant organisms, which are already a significant problem at some institutions.
Insights
Doripenem, a new carbapenem antibiotic, shows broad-spectrum activity against many bacteria, including resistant strains. It is approved for intra-abdominal and urinary tract infections, with a low risk of seizures.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Carbapenems are crucial antibiotics for treating severe bacterial infections.
- Doripenem is a recently developed carbapenem with a distinct antimicrobial profile.
Purpose of the Study:
- To review the antimicrobial spectrum, clinical applications, and safety profile of doripenem.
- To identify areas requiring further research regarding doripenem's use.
Main Methods:
- In vitro susceptibility testing against various bacterial pathogens.
- Review of clinical trial data for efficacy and safety.
- Pharmacodynamic considerations, including infusion strategies.
Main Results:
- Doripenem exhibits potent in vitro activity against Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter species, and Bacteroides fragilis.
- It demonstrates activity against extended-spectrum beta-lactamase-producing strains but not against methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci.
- Resistant P. aeruginosa mutants are less readily selected with doripenem compared to other carbapenems. Doripenem has a low propensity to cause seizures.
Conclusions:
- Doripenem is effective for complicated intra-abdominal and urinary tract infections.
- Further studies are needed to establish optimal dosing for specific populations (neonatal, pediatric, cystic fibrosis) and renal replacement therapies.
- The long-term utility of doripenem depends on controlling the spread of carbapenem-resistant organisms.
Related Concept Videos
Diphtheria
Inhibitors of Gram-positive Cell Wall Synthesis
Acute Pyelonephritis II: Diagnostic Studies and Management
Antibiotic Selection
Antimicrobial Effectiveness
Acute Pyelonephritis I: Introduction